DISEASE INDICATIONS: Psoriasis
MANUFACTURER: AbbVie Ltd
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Therapeutic Goods Administration (TGA)
Skyrizi (risankizumab) is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a monoclonal antibody that works by blocking the interleukin-23 (IL-23) pathway, which is involved in the development and progression of psoriasis.
